Stugeron (Cinnarizine) 25 mg, 50 pcs.

1 tablet contains:

Active substances:

Cinnarizine - 25 mg.

Excipients:

silica colloidal

potato starch,

magnesium stearate,

povidone

talc,

corn starch,

lactose monohydrate.

Pharmacodynamics

Selective calcium channel blocker, class IV. Improves cerebral, coronary and peripheral blood circulation; improves microcirculation.

By inhibiting the entry of calcium ions into the smooth muscle cells of blood vessels, it reduces the tone of the smooth muscle membrane of arterioles; reduces their sensitivity to biogenic vasoconstrictor substances (adrenaline, norepinephrine), bradykinin. Reduces the excitability of the vestibular apparatus. It is characterized by high tropism to the vessels of the brain. It improves microcirculation, increasing the deformability of red blood cells and reducing high blood viscosity. It has moderate antihistamine activity.

Pharmacokinetics

Suction

After oral administration, C max of cinnarizine in plasma is noted after 1-3 hours.

Distribution

Plasma protein binding is 91%.

Metabolism

Cinnarizine is completely metabolized.

Breeding

T 1/2 is 4 hours. It is excreted in the form of metabolites: 1/3 - by the kidneys, 2/3 - through the intestine.

• Treatment and prevention of cerebrovascular accidents: cerebral atherosclerosis, conditions after strokes, traumatic brain injuries, dyscirculatory encephalopathy;
• labyrinthine disorders (for maintenance therapy for dizziness, tinnitus, nystagmus, nausea, vomiting);
• kinetosis prevention;
• migraine prophylaxis;
• treatment and prevention of peripheral circulatory disorders: illness and Raynaud's syndrome; acrocyanosis, intermittent claudication, trophic disorders, trophic and varicose ulcers, diabetic angiopathy, paresthesias, microcirculation disorders;
• as part of complex therapy in the following cases: rapid mental fatigue, irritability, decreased mood, memory impairment and ability to concentrate.

Despite the fact that a teratogenic effect of Stugeron was not established in an animal study, the use of the drug during pregnancy is possible only in exceptional cases, when the expected benefit to the mother significantly exceeds the potential risk to the fetus.

It is not known whether Cinnarizine is excreted in breast milk, so the use of Stugeron during lactation (breastfeeding) is not recommended.

Hypersensitivity to the drug. Erythematous lupus.

From the digestive system: dyspepsia, dry mouth; in isolated cases - cholestatic jaundice.

From the side of the central nervous system: rarely - headache; in patients of senile age with prolonged use of Stugeron, extrapyramidal syndromes and depression are possible (in such cases, treatment should be interrupted).

Other: allergic reactions, weight gain, increased sweating; in isolated cases - lupus-like syndrome, lichen planus.

With the combined use of Stugeron and ethanol (or ethanol-containing drugs), antihypertensive, nootropic and vasodilator drugs, other drugs that have a depressing effect on the central nervous system (tricyclic antidepressants, hypnotics, sedatives), an increase in their effect is noted.

Install individually. The optimal therapeutic dose should be continued gradually. The maximum daily dose is 225 mg (9 tablets).

The drug should be taken after meals.

Children aged 6-12 years are prescribed half the dose for adults.

In cases of cerebrovascular accident

Adults are prescribed 25-50 mg 3 times / day.

With peripheral circulation disorders

Assign 50-75 mg 3 times / day.

For labyrinthine disorders

Assign 25 mg 3 times / day.

For the prevention of kinetosis

Adults are prescribed 25 mg 30 minutes before the trip with repeated administration every 6 hours.

Symptoms: vomiting, drowsiness, tremor, arterial hypotension, coma.

Treatment: gastric lavage, the appointment of activated carbon; conduct symptomatic therapy. There is no specific antidote.

In Parkinson's disease, Stugeron is prescribed only in exceptional cases, when the expected benefit significantly exceeds the potential risk.

Stugeron, due to the presence of an antihistamine effect, can neutralize positive reactions during skin diagnostic tests. In this regard, 4 days before the samples, the drug should be discontinued.

Patients taking the drug are not allowed to drink alcohol.

Laboratory monitoring

With prolonged use of Stugeron, it is recommended to monitor laboratory blood parameters and liver and kidney function indicators.

Influence on the ability to drive vehicles and other mechanisms requiring increased concentration of attention

Patients taking the drug should be careful when practicing activities that require increased attention and speed of psychomotor reactions.

Stugeron tablets are white or almost white, round, flat, with a bevel, almost odorless, with the engraving "STUGERON" on one side and with a risk for breaking on the other.